bioRxivMicrobiology
P1 bacteriophage-enabled delivery of CRISPR-Cas9 antimicrobial activity against Shigella flexneri
Y. W. Huan, V. Torraca, R. Brown, J. Fa-arun, S. L. Miles, D. A. Oyarzun, S. Mostowy, B. Wang
Abstract
The discovery of clustered, regularly interspaced, short palindromic repeats (CRISPR) and the Cas9 RNA-guided nuclease provides unprecedented opportunities to selectively kill specific populations or species of bacteria. However, the use of CRISPR-Cas9 to clear bacterial infections in vivo is hampered by the inefficient delivery of cas9 genetic constructs into bacterial cells. Here, we use a broad-host-range P1-derived phagemid to deliver the CRISPR-Cas9 chromosomal-targeting system into Escherichia coli and the dysentery-causing Shigella flexneri to achieve DNA sequence-specific killing of targeted bacterial cells. We show that genetic modification of the helper P1 phage DNA packaging site (pac) significantly enhances the purity of packaged phagemid and improves the Cas9-mediated killing of S. flexneri cells. We further demonstrate that P1 phage particles can deliver chromosomal-targeting cas9 phagemids into S. flexneri in vivo using a zebrafish larvae infection model, where it significantly reduces the bacterial load and promotes host survival. Our study highlights the potential of combining a P1 bacteriophage-based delivery with the CRISPR chromosomal-targeting system to achieve DNA sequence-specific cell lethality and efficient clearance of bacterial infection.
- organism: zebrafish
- assay: CRISPR screen
- research focus: host-pathogen & immune response
- research focus: perturbation response prediction
- approach: experimental assay
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The host range and the role of O-antigen in P1 transduction with its alternative S' tail fibre
Y. W. Huan, J. Fa-arun, B. Wang·bioRxiv·Jul 24, 2022
- A nucleus-like compartment shields bacteriophage DNA from CRISPR-Cas and restriction nucleases
S. D. Mendoza, J. D. Berry, … J. Bondy-Denomy·bioRxiv·Jul 17, 2018
- CRISPR-Cas9 modified bacteriophage for treatment of Staphylococcus aureus induced osteomyelitis and soft tissue infection
L. K. Horstemeyer, J. Park, … L. B. Priddy·bioRxiv·Jul 18, 2019
- Programming CRISPRi-dCas9 to control the lifecycle of bacteriophage T7
Tobias Bergmiller·bioRxiv·May 15, 2024
- Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome
K. N. Lam, P. Spanogiannopoulos, … P. J. Turnbaugh·Cell ReportsPeer-reviewed·Nov 1, 2021
- A Minimal Packaging Signal Enables Production of High-Purity Phage-Like Particles for CRISPR-Cas Antimicrobials in Staphylococcus aureus
David S. Dooley, Hannah Boyd, Cong T. Trinh·bioRxiv·Jun 29, 2026